Open Access Email this article to a friend

Capecitabine in combination with oxaliplatin and bevacizumab (AXELOX) as 1st line treatment for fit and vulnerable elderly patients (aged >70 years) with metastatic colorectal cancer (mCRC): a multicenter phase II study of the Hellenic Oncology Research Group (HORG)

Lambros Vamvakas, Alexios Matikas, Athanasios Karampeazis, Dora Hatzidaki, Stelios Kakolyris, Charalampos Christophylakis, Ioannis Boukovinas, Aris Polyzos, Vassilis Georgoulias and John Souglakos*

BMC Cancer 2014, 14:277  doi:10.1186/1471-2407-14-277

Fields marked * are required

Multiple email addresses should be separated with commas or semicolons.
How can I ensure that I receive BMC Cancer's emails?